SCHEMBL3775823

SCHEMBL3775823

CCc1ccc(NC(=NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SRC P12931 1/20 0.41
RAB9A P51151 3/20 0.41
FAAH O00519 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
MAPK14 Q16539 1/20 0.40
NAMPT P43490 2/20 0.40
NR1H4 Q96RI1 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13785636 1.00 CYP17A1 (0.47) CYP17A1MEN1KMT2ASRCRAB9A
SCHEMBL3775821 1.00 CYP17A1 (0.47) CYP17A1MEN1KMT2ASRCRAB9A
SCHEMBL3787072 0.92 CYP17A1 (0.47) CYP17A1RAB9AMAPK14NAMPTNR1H4
SCHEMBL13017220 0.92 CYP17A1 (0.47) CYP17A1RAB9AMAPK14NAMPTNR1H4
SCHEMBL22416639 0.91 CYP17A1 (0.46) CYP17A1MEN1KMT2AMAPK14NAMPT
SCHEMBL5278861 0.90 CYP17A1 (0.45) CYP17A1NAMPTNR1H4PTPN11CA1
SCHEMBL5278856 0.90 CYP17A1 (0.45) CYP17A1NAMPTNR1H4PTPN11CA1
SCHEMBL10092627 0.89 CYP17A1 (0.48) CYP17A1SMN1; SMN2NAMPTNR1H4HDAC3
SCHEMBL14155353 0.89 CYP17A1 (0.48) CYP17A1SMN1; SMN2NAMPTNR1H4HDAC3
Hydrochloric Acid SCHEMBL5678163 0.89 CYP17A1 (0.44) CYP17A1NAMPTNR1H4PTPN11CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331384-A1 GUANIDINE BASED COMPOUNDS UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) 2010-12-30 US disclosed
US-20100331384-A1 GUANIDINE BASED COMPOUNDS UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) 2010-12-30 US disclosed
WO-2009080818-A2 GUANIDINE BASED COMPOUNDS THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331384-A1 GUANIDINE BASED COMPOUNDS ADRB2, ADRA2A, ADRA2C CYP17A1 3857/4885MEN1 4796/4885KMT2A 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.